A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.
Melinda A PruisMatthew G KrebsRuth PlummerFilip Yves Francine De VosEric AngevinHans PrenenMartin D ForsterGlen ClackAnnegret Van der AaMarc TjwaEllen JansenTimothy PereraMartijn Paul LolkemaPublished in: The oncologist (2023)
OMO-1 was tolerated at the dose of 250 mg BID and shows initial signs of MET inhibition and anti-tumor activity in METex14 mutated NSCLC patients.
Keyphrases
- tyrosine kinase
- small cell lung cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- clinical trial
- chronic kidney disease
- squamous cell carcinoma
- prognostic factors
- optical coherence tomography
- peritoneal dialysis
- advanced non small cell lung cancer
- epidermal growth factor receptor
- phase iii
- study protocol
- patient reported outcomes
- protein kinase
- phase ii
- brain metastases